Compare FSV & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSV | APLS |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.2B |
| IPO Year | 2015 | 2015 |
| Metric | FSV | APLS |
|---|---|---|
| Price | $141.43 | $40.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 21 |
| Target Price | ★ $210.67 | $32.71 |
| AVG Volume (30 Days) | 149.5K | ★ 7.2M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | $7.45 | N/A |
| Revenue Next Year | $6.77 | $18.21 |
| P/E Ratio | ★ $49.49 | $202.05 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $133.42 | $16.10 |
| 52 Week High | $205.99 | $40.48 |
| Indicator | FSV | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 87.73 |
| Support Level | $133.42 | $19.38 |
| Resistance Level | $158.68 | N/A |
| Average True Range (ATR) | 3.88 | 0.52 |
| MACD | 0.80 | 2.91 |
| Stochastic Oscillator | 70.57 | 99.77 |
FirstService Corp is engaged in outsourcing property services. The company operates in two business divisions: FirstService Residential and FirstService Brands. FirstService Residential has service contracts to manage thousands of residential communities, including high and low-rise condominiums and co-operatives. FirstService Brands generates the majority of the company's revenue and provides property services to residential and commercial customers through the following brands: California Closets; Paul Davis Restoration; CertaPro Painters, Floor Coverings International, and Pillar to Post Home Inspectors. The company earns the majority of its revenue in the United States, with the remaining revenue generated in Canada.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).